Lustra
Company: Medicis PharmaceuticalApproval Status: Approved January 1998
Treatment for: ultraviolet-induced skin discolorations
Areas: Dermatology / Plastic Surgery
| General Information | Clinical Results | Mechanism of Action |
General Information
Lustra has been approved for the treatment of ultraviolet-induced skin discolorations and hyperpigmentation associated with pregnancy, superficial trauma and the use of oral contraceptives and hormone replacement therapy.
Clinical Results
In clinical studies, Lustra demonstrated substantial reduction in pigmented lesions in a two-week period, and the reservoir effect of Lustra reduced damage from ultraviolet radiation versus placebo.
Mechanism of Action
Lustra contains 4% hydroquinone in a vehicle containing glycolic acid and an antioxidant complex.
Lustra Drug Information
The Lustra drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
